Florida hospital treats DMD patient with new, $3.2M gene therapy

For the first time in Florida, physicians administered a recently approved gene therapy for Duchenne muscular dystrophy to a pediatric patient. 

Providers at Nemours Children's Hospital in Orlando treated a DMD patient with Sarepta Therapeutics' Elevidys (delandistrogene moxeparvovec-rokl), which the FDA approved June 22 for 4- and 5-year-olds with a DMD gene mutation. The treatment costs $3.2 million.

Elevidys is the first and only approved gene therapy for the rare genetic condition that weakens the body's muscles. DMD mostly affects males, and between 9,000 and 12,000 people in the U.S. are diagnosed with it, according to Nemours Children's Hospital. 

"Until now, patients have only had treatments to manage their symptoms," the hospital said in a Sept. 26 news release.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars